OR33-07 Association Between Triglyceride Glucose Index and Chronic Kidney Disease Progression Among Type 2 Diabetes Mellitus Patients: A Single-Center Retrospective Cohort Study

Abstract Disclosure: E.M. Gonzales: None. O.C. Dampil: None. Background: Type 2 Diabetes Mellitus’ (T2DM) rising prevalence and complications including chronic kidney disease (CKD), pose significant healthcare challenges. The triglyceride glucose (TyG) index, a non-invasive and cost-effective marker of insulin resistance, has gained attention for its potential role in predicting renal complications in T2DM. This study aimed to explore the relationship between the TyG index and CKD progression in T2DM patients, aiming to inform clinical decisions and personalized treatment strategies. Additionally, the study aimed to determine the incidence of CKD progression among T2DM patient and to compare the demographics and clinical characteristics by CKD progression. Methodology: This study included 971 T2DM patients to assess the association between the TyG index and 1-year CKD progression. Data were processed in Stata MP17, with continuous variables presented as median and categorical variables as frequencies. The Mann-Whitney U test, Chi-square and fisher exact test were used to compare groups. The optimal TyG cutoff was determined using Youden’s curve. Multivariable regression identified association adjusting for confounders. Statistical significance was set at ≤ 0.05. Results: Among 971 T2DM patients, 220 developed CKD progression within one year, with an incidence rate of 22.66% (95% CI: 20.06-25.42%). Patients with CKD progression were significantly older (median 61 vs. 56 years, p<0.00001) and had higher baseline levels of creatinine (0.9 vs. 0.8 mg/dL, p=0.0001, UACR (19.1 vs. 12.6, p=0.0002), HbA1c (6.8% vs. 6.7%, p=0.0417), and fasting blood sugar (119 vs. 114 mg/dL, p=0.0047), while eGFR was lower (87.4 vs. 96.2 mL/min, p<0.00001). It was also observed that a higher proportion of patients with CKD progression had vitamin D deficiency. The TyG index was significantly higher in patients with CKD progression (9.0 vs. 8.9, p=0.015), with an optimal cutoff of >9.33 (sensitivity 31.82%, specificity 77.50%). Patients with TyG index >9.33 had a 44% higher risk of CKD progression (Adjusted RR: 1.44, p=0.002) even after adjusting for confounders. Other significant risk factors included older age and prior CKD history. Conclusion: This study demonstrates that a higher TyG index is significantly associated with an increased risk of CKD progression in patients with T2DM. TyG index >9.33 predicts 44% higher risk of CKD progression. These findings highlight the potential role of the TyG index as a predictive marker for CKD progression, emphasizing the need for early identification and targeted interventions in high-risk T2DM patients. Presentation: Monday, July 14, 2025